Chrysostomi Gialeli
Title
Cited by
Cited by
Year
Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting
C Gialeli, AD Theocharis, NK Karamanos
The FEBS journal 278 (1), 16-27, 2011
15502011
Extracellular matrix structure
AD Theocharis, SS Skandalis, C Gialeli, NK Karamanos
Advanced drug delivery reviews 97, 4-27, 2016
11242016
Glycosaminoglycans: key players in cancer cell biology and treatment#
N Afratis, C Gialeli, D Nikitovic, T Tsegenidis, E Karousou, AD Theocharis, ...
FEBS Journal, 2012
4842012
Emerging aspects of nanotoxicology in health and disease: from agriculture and food sector to cancer therapeutics
Z Piperigkou, K Karamanou, AB Engin, C Gialeli, AO Docea, DH Vynios, ...
Food and Chemical Toxicology 91, 42-57, 2016
892016
Cell–matrix interactions: focus on proteoglycan–proteinase interplay and pharmacological targeting in cancer
AD Theocharis, C Gialeli, P Bouris, E Giannopoulou, SS Skandalis, ...
The FEBS journal 281 (22), 5023-5042, 2014
842014
Syndecans as modulators and potential pharmacological targets in cancer progression
D Barbouri, N Afratis, C Gialeli, DH Vynios, AD Theocharis, N Karamanos
Frontiers in oncology 4, 4, 2014
842014
Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid
PG Dedes, C Gialeli, AI Tsonis, I Kanakis, AD Theocharis, D Kletsas, ...
Biochimica et Biophysica Acta (BBA)-General Subjects 1820 (12), 1926-1939, 2012
742012
Evaluation of the coordinated actions of estrogen receptors with epidermal growth factor receptor and insulin‐like growth factor receptor in the expression of cell surfaceá…
AI Tsonis, N Afratis, C Gialeli, MI Ellina, Z Piperigkou, SS Skandalis, ...
The FEBS journal 280 (10), 2248-2259, 2013
602013
Imatinib as a key inhibitor of the platelet‐derived growth factor receptor mediated expression of cell surface heparan sulfate proteoglycans and functional properties of breastá…
CJ Malavaki, AE Roussidis, C Gialeli, D Kletsas, T Tsegenidis, ...
The FEBS journal 280 (10), 2477-2489, 2013
492013
PDGF/PDGFR signaling and targeting in cancer growth and progression: focus on tumor microenvironment and cancer-associated fibroblasts
C Gialeli, D Nikitovic, D Kletsas, A D Theocharis, G N Tzanakakis, ...
Current pharmaceutical design 20 (17), 2843-2848, 2014
472014
Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies
CH Gialeli, D Kletsas, D Mavroudis, HP Kalofonos, GN Tzanakakis, ...
Current medicinal chemistry 16 (29), 3797-3804, 2009
392009
Advances and advantages of nanomedicine in the pharmacological targeting of hyaluronan-CD44 interactions and signaling in cancer
SS Skandalis, C Gialeli, AD Theocharis, NK Karamanos
Advances in cancer research 123, 277-317, 2014
332014
Inhaled chemotherapy in lung cancer: safety concerns of nanocomplexes delivered
P Zarogoulidis, C Gialeli, NK Karamanos
Therapeutic delivery 3 (9), 1021-1023, 2012
312012
Complement inhibitor CSMD1 acts as tumor suppressor in human breast cancer
A Escudero-Esparza, M Bartoschek, C Gialeli, M Okroj, S Owen, ...
Oncotarget 7 (47), 76920, 2016
302016
1.1 Extracellular matrix: a functional scaffold
A Theocharis, C Gialeli, V Hascall, NK Karamanos
Extracellular matrix: pathobiology and signaling, 3-20, 2012
282012
Synthesis and ┼valuation of ┴nticancer ┴ctivity in Cells of Novel Stoichiometric Pegylated Fullerene-Doxorubicin Conjugates
GE Magoulas, M Bantzi, D Messari, E Voulgari, C Gialeli, D Barbouri, ...
Pharmaceutical research 32 (5), 1676-1693, 2015
262015
Expression of matrix macromolecules and functional properties of EGF-responsive colon cancer cells are inhibited by panitumumab
C Gialeli, AD Theocharis, D Kletsas, GN Tzanakakis, NK Karamanos
Investigational new drugs 31 (3), 516-524, 2013
262013
Novel potential inhibitors of complement system and their roles in complement regulation and beyond
C Gialeli, B Gungor, AM Blom
Molecular immunology 102, 73-83, 2018
252018
The role of oligodendrocytes in the molecular pathobiology and potential molecular treatment of cervical spondylotic myelopathy
SK Karadimas, CH Gialeli, G Klironomos, GN Tzanakakis, ...
Current medicinal chemistry 17 (11), 1048-1058, 2010
242010
Cartilage Oligomeric Matrix Protein initiates cancer stem cells through activation of Jagged1-Notch3 signaling
KS Papadakos, M Bartoschek, C Rodriguez, C Gialeli, SB Jin, U Lendahl, ...
Matrix Biology 81, 107-121, 2019
222019
The system can't perform the operation now. Try again later.
Articles 1–20